Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We saw a sequential reduction in inventory volumes in the third quarter and we will see continued improvement in the coming quarter as well |
| Based upon our improved performance, we are further raising the outlook for both sales and profitability for the full year 2023 |
| The improvements were across all business segments and all regions and the result of our ongoing actions to strengthen execution |
| So, on Q4, we have said it's going to be a significant improvement on the minus 9% |
| I think, as you rightly pointed out, you know, we are pretty pleased with the progress we've made on margins in D&T |
| I think it's positive that we have that dialog because the moment we can clarify, we can then test, we can also satisfy their needs |
| Our improved performance reinforces the confidence we have in delivering also the next two years of our three years plan to create value with sustainable impact |
| The strong comparable sales growth of 11% was driven by 14% growth in Diagnosis and Treatment, 10% growth in Connected Care, and 7% in Personal Health |
| Our adjusted EBITDA margin was 10.2%, a strong improvement of 540 basis points versus a year ago |
| Therefore, I also mentioned that actually we are ahead of the first year of our three-year plan, and actually this have given us further confidence in also executing the second and third year of the plan that I presented in January |
| It also gives us confidence in the execution of the second and third year of our plan, as we see the actions we are taking really having an impact both on supporting strong sales, supporting also margin improvement, and productivity, you see dialing back into our profitability step up |
| Our order book remains strong |
| The fundamentals of the markets in which we operate, as well as our order funnel are healthy, and our innovation portfolio is strategically positioned to help hospitals address their staffing shortages, enhance productivity, and improve patient outcomes |
| So, if you look to the IGT side, if you look to Ultrasound, we have very strong positions and actually also even this year, we continue to see that progress |
| The order book remains around 20% higher than in Q3 2021, when the global supply chain crisis started, and will continue to support revenue growth |
| So, I think we need to be specific that, of course, in our D&T businesses, there are several businesses where actually we are from a market share perspective very strong and also leading and winning |
| So, we had a very strong start of the year in China, as you have seen, right? We grew orders and revenue double-digit, and that was good momentum that we saw because of pan demand and also strong progress we made on our local for local portfolio |
| But fundamentally the factors that we told you about, you know, and we have been saying from the start of the year, the improvement in the supply chain on patient safety and quality and productivity, you see that quarter-on-quarter that coming back |
| We celebrated 100 years of successful presence and collaboration in China, where we are known as Philipu, and have a leading position, a strong local team of over 7,000 employees, and an extensive footprint covering manufacturing, innovation, sales, and services |
| It was a fourth quarter of growth that you have seen, and that actually really increases our confidence to also increase the guidance second time this year towards a strong close of this year, which would bring us ahead of the first-year plan that we announced in January |
| It's hard to say how exactly it will pan out, but we are very confident on the Chinese market and that it will resume and that we will also -- we will be able to then resume our trajectory that we had in China, as it's fundamentally very attractive and we see great prospects |
| Secondly, we have an improvement where we see that the order intake as we also mentioned earlier will come off in Q4, and also we expect that to continue in 2024, as the underlying fundamentals of the market and our positioning has not changed |
| So, therefore, there is a big part that we have -- let's say, we have had a good start to the year and therefore, we expect quarter-over-quarter, of course, improvement in Q4, but we are not specifying whether we are going to be -- to the last amount at this stage |
| Connected Care comparable sales increased by 10% driven by double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics |
| Connected Care adjusted EBITA margin was 3.7% over 1,100 basis points improvement from last year, mainly driven by increased sales and productivity measures |
| That also is fueling our strong sales performance to date and four quarters of improved sales growth |
| So, as said by Abhijit, first of all, we have still a very strong order book, which is 20% higher than two years ago |
| We will do that in full collaboration and we also see actually this as a positive development because the clearer we can get on what is still outstanding to be answered, actually that helps us to take those questions off the table |
| Adjusted EBITA margin for Personal Health was 18.7%, an increase of 460 basis points, driven by operational leverage, pricing, and productivity measures |
| So, as I said earlier, we did see very strong momentum and actually pent-up demand from even the COVID period |
| Statement |
|---|
| Order intake, which accounts for around 40% of Group sales was lower in the quarter, mainly due to the comparison base related to the exceptionally high orders in 2021 and 2022, substantially lower China, and longer order-to-delivery lead times |
| In Diagnosis and Treatment comparable order intake declined low double-digit following high order intake in Q3 2022, significantly lower orders in China and Russia, as well as longer order-to-delivery lead times |
| Order intake was mid-single digit lower year-on-year in Connected Care due to the tough comps in hospital patient monitoring after the expansion and renewal of the installed base in the last few years |
| This impacted short-term decision-making by hospitals as they work through the government measures, resulting in a substantially lower order intake year-on-year |
| We continue to see hospital healthcare systems in the US and other mature geographies exhibit cautious buying behavior in the short term, and China is heavily impacted by the government-initiated anti-corruption measures |
| We also saw it materializing |
| In China, the lower orders are due to the impact of the recent government-imposed anti-corruption measures |
| Overall, consumer sentiment remained subdued |
| Now, then indeed, there is this current short-term slowdown as hospitals work through the anti-corruption measures |
| I also shared that actually we were working on high-risk components because what we were facing is that, because of the misses of some components, we could not complete and then not deliver |
| That has been something that we have been constantly working on and in fact, even challenged on |
| Like I said, because of the uncertainties that we have |
| So, if you exclude D&T -- if you exclude China, it's still a decline this year in the third quarter |
| Then, indeed we have the MR pressure on lead time |
| Although recognizing uncertainties remain in increasingly volatile geopolitical environment |
| Although recognizing that uncertainties remain in an increasingly volatile geopolitical environment |
| Before we go into the numbers, I want to say that our hearts go out to everyone affected by the terrible events ongoing in the Middle East |
| As explained in the last quarter, the Russia impact is due to the longer order lead time because of additional export control procedures that have been put in place recently |
| There are also a lot of uncertainties out there, as we have highlighted |
| And then also on your comments on long lead times impacting order intake, is it simply you losing orders to competitors who can deliver faster? I just want to make sure I'm not missing anything in terms of what this actually implies |
Please consider a small donation if you think this website provides you with relevant information